PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31444999-14	2019	Ponatinib treatment significantly increased plasma VEGF, soluble (s)VEGFR1, sVEGFR2, sTIE2, interferon gamma (IFNgamma), tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-6, IL-8, and IL-10 and decreased sVEGFR2.	ponatinib	0-9	tumor necrosis factor	Homo sapiens	121-148	
31444999-14	2019	Ponatinib treatment significantly increased plasma VEGF, soluble (s)VEGFR1, sVEGFR2, sTIE2, interferon gamma (IFNgamma), tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-6, IL-8, and IL-10 and decreased sVEGFR2.	ponatinib	0-9	tumor necrosis factor	Homo sapiens	150-159	
25996294-7	2015	Ponatinib and pazopanib abrogated phosphorylation of mixed lineage kinase domain-like protein (MLKL) upon TNF-alpha-induced necroptosis, indicating that both agents target a component upstream of MLKL.	ponatinib	0-9	tumor necrosis factor	Homo sapiens	106-115	
25801024-3	2015	Ponatinib potently inhibited multiple paradigms of RIPK1- and RIPK3-dependent cell death and inflammatory tumor necrosis factor alpha (TNF-alpha) gene transcription.	ponatinib	0-9	tumor necrosis factor	Homo sapiens	106-133	
25801024-3	2015	Ponatinib potently inhibited multiple paradigms of RIPK1- and RIPK3-dependent cell death and inflammatory tumor necrosis factor alpha (TNF-alpha) gene transcription.	ponatinib	0-9	tumor necrosis factor	Homo sapiens	135-144